| Primary |
| Multiple Sclerosis |
44.1% |
| Product Used For Unknown Indication |
34.2% |
| Relapsing-remitting Multiple Sclerosis |
6.6% |
| Premedication |
2.5% |
| Hypertension |
2.4% |
| Depression |
2.0% |
| Pain |
1.6% |
| Muscle Spasms |
0.7% |
| Diabetes Mellitus |
0.7% |
| Blood Cholesterol Increased |
0.7% |
| Anxiety |
0.6% |
| Drug Use For Unknown Indication |
0.5% |
| Convulsion |
0.5% |
| Migraine |
0.5% |
| Headache |
0.4% |
| Hypothyroidism |
0.4% |
| Fatigue |
0.4% |
| Secondary Progressive Multiple Sclerosis |
0.4% |
| Prophylaxis |
0.4% |
| Asthma |
0.4% |
|
| Multiple Sclerosis Relapse |
12.3% |
| Urinary Tract Infection |
10.6% |
| Vomiting |
6.5% |
| Weight Decreased |
5.9% |
| Pneumonia |
5.3% |
| Injection Site Erythema |
5.2% |
| Influenza Like Illness |
4.8% |
| Multiple Sclerosis |
4.6% |
| Pain |
4.6% |
| Pyrexia |
4.3% |
| Injection Site Pain |
4.2% |
| Optic Neuritis |
4.2% |
| White Blood Cell Count Decreased |
3.8% |
| Myocardial Infarction |
3.6% |
| Convulsion |
3.5% |
| Suicidal Ideation |
3.5% |
| Pain In Extremity |
3.4% |
| Tremor |
3.4% |
| Vision Blurred |
3.3% |
| Fatigue |
3.0% |
|
| Secondary |
| Multiple Sclerosis |
33.9% |
| Product Used For Unknown Indication |
27.9% |
| Relapsing-remitting Multiple Sclerosis |
5.7% |
| Premedication |
4.8% |
| Depression |
4.7% |
| Hypertension |
4.5% |
| Pain |
3.1% |
| Drug Use For Unknown Indication |
1.7% |
| Blood Cholesterol Increased |
1.6% |
| Muscle Spasms |
1.6% |
| Anxiety |
1.5% |
| Diabetes Mellitus |
1.2% |
| Fatigue |
1.1% |
| Migraine |
1.0% |
| Hypothyroidism |
1.0% |
| Headache |
1.0% |
| Convulsion |
0.9% |
| Asthma |
0.9% |
| Sleep Disorder |
0.9% |
| Insomnia |
0.8% |
|
| Multiple Sclerosis Relapse |
14.0% |
| Urinary Tract Infection |
9.1% |
| Influenza Like Illness |
8.5% |
| Injection Site Erythema |
6.3% |
| Vomiting |
6.2% |
| Weight Decreased |
4.7% |
| Pain |
4.6% |
| Suicidal Ideation |
4.4% |
| Tremor |
4.2% |
| Injection Site Pain |
4.1% |
| Fatigue |
4.0% |
| Headache |
4.0% |
| White Blood Cell Count Decreased |
3.9% |
| Pneumonia |
3.9% |
| Pyrexia |
3.8% |
| Hepatic Enzyme Increased |
3.4% |
| Optic Neuritis |
3.0% |
| Nausea |
2.9% |
| Pain In Extremity |
2.5% |
| Vision Blurred |
2.5% |
|
| Concomitant |
| Multiple Sclerosis |
63.6% |
| Product Used For Unknown Indication |
10.9% |
| Depression |
3.7% |
| Gait Disturbance |
2.7% |
| Anticoagulant Therapy |
2.2% |
| Pain |
2.2% |
| Drug Use For Unknown Indication |
1.9% |
| Hypertension |
1.5% |
| Muscle Spasms |
1.4% |
| Relapsing-remitting Multiple Sclerosis |
1.4% |
| Anxiety |
1.1% |
| Contraception |
1.0% |
| Insomnia |
0.9% |
| Prophylaxis |
0.9% |
| Osteoporosis |
0.8% |
| Restless Legs Syndrome |
0.8% |
| Adverse Event |
0.7% |
| Trigeminal Neuralgia |
0.7% |
| Back Pain |
0.7% |
| Muscle Spasticity |
0.7% |
|
| Multiple Sclerosis Relapse |
14.9% |
| Urinary Tract Infection |
10.2% |
| Fatigue |
5.9% |
| Multiple Sclerosis |
5.9% |
| Weight Decreased |
5.3% |
| Headache |
5.0% |
| Convulsion |
4.7% |
| Vomiting |
4.7% |
| Pulmonary Embolism |
4.0% |
| Breast Cancer |
3.7% |
| Pain In Extremity |
3.7% |
| Pyrexia |
3.7% |
| Urticaria |
3.7% |
| Visual Impairment |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Asthenia |
3.4% |
| Muscular Weakness |
3.4% |
| Nausea |
3.4% |
| Progressive Multifocal Leukoencephalopathy |
3.4% |
| Tremor |
3.4% |
|
| Interacting |
| Product Used For Unknown Indication |
47.1% |
| Multiple Sclerosis |
29.4% |
| Contraception |
5.9% |
| Convulsion |
5.9% |
| Hordeolum |
5.9% |
| Smoking Cessation Therapy |
5.9% |
|
| Pancreatitis Chronic |
40.0% |
| Injection Site Haematoma |
20.0% |
| Vomiting |
20.0% |
| White Blood Cell Count Increased |
20.0% |
|
